King's College London

Research portal

Cationic Liposome- Multi-Walled Carbon Nanotubes Hybrids for Dual siPLK1 and Doxorubicin Delivery In Vitro

Research output: Contribution to journalArticle

Standard

Cationic Liposome- Multi-Walled Carbon Nanotubes Hybrids for Dual siPLK1 and Doxorubicin Delivery In Vitro. / Pereira, Sara; Lee, Jin; Rubio , Noelia; Hassan, Hatem A F M; Suffian, Izzat Bin Mohamed; Wang, Julie T W; Klippstein Martin, Rebecca; Ballesteros, Belén; Al-Jamal, Wafa' T.; Al-Jamal, Khuloud T.

In: Pharmaceutical Research, Vol. 32, No. 10, 10.2015, p. 3293-3308.

Research output: Contribution to journalArticle

Harvard

Pereira, S, Lee, J, Rubio , N, Hassan, HAFM, Suffian, IBM, Wang, JTW, Klippstein Martin, R, Ballesteros, B, Al-Jamal, WT & Al-Jamal, KT 2015, 'Cationic Liposome- Multi-Walled Carbon Nanotubes Hybrids for Dual siPLK1 and Doxorubicin Delivery In Vitro', Pharmaceutical Research, vol. 32, no. 10, pp. 3293-3308. https://doi.org/10.1007/s11095-015-1707-1

APA

Pereira, S., Lee, J., Rubio , N., Hassan, H. A. F. M., Suffian, I. B. M., Wang, J. T. W., ... Al-Jamal, K. T. (2015). Cationic Liposome- Multi-Walled Carbon Nanotubes Hybrids for Dual siPLK1 and Doxorubicin Delivery In Vitro. Pharmaceutical Research, 32(10), 3293-3308. https://doi.org/10.1007/s11095-015-1707-1

Vancouver

Pereira S, Lee J, Rubio N, Hassan HAFM, Suffian IBM, Wang JTW et al. Cationic Liposome- Multi-Walled Carbon Nanotubes Hybrids for Dual siPLK1 and Doxorubicin Delivery In Vitro. Pharmaceutical Research. 2015 Oct;32(10): 3293-3308. https://doi.org/10.1007/s11095-015-1707-1

Author

Pereira, Sara ; Lee, Jin ; Rubio , Noelia ; Hassan, Hatem A F M ; Suffian, Izzat Bin Mohamed ; Wang, Julie T W ; Klippstein Martin, Rebecca ; Ballesteros, Belén ; Al-Jamal, Wafa' T. ; Al-Jamal, Khuloud T. / Cationic Liposome- Multi-Walled Carbon Nanotubes Hybrids for Dual siPLK1 and Doxorubicin Delivery In Vitro. In: Pharmaceutical Research. 2015 ; Vol. 32, No. 10. pp. 3293-3308.

Bibtex Download

@article{32b7722a89274a84a96189da89a2c4ae,
title = "Cationic Liposome- Multi-Walled Carbon Nanotubes Hybrids for Dual siPLK1 and Doxorubicin Delivery In Vitro",
abstract = "PURPOSE: To formulate f-MWNTs-cationic liposome hybrids for the simultaneous delivery of siPLK1 and doxorubicin to cancer cells.METHOD: f-MWNTs-cationic liposome hybrids were prepared by the thin film hydration method where the lipid film was hydrated with 100 μg/ml or 1 mg/ml of ox-MWNTs-NH3 (+) or MWNTs-NH3 (+) in 5{\%} dextrose. siRNA complexation and protection ability was determined by agarose gel electrophoresis. f-MWNTs and liposome interaction was evaluated using Nile Red (NR) fluorescence spectroscopy. Cellular uptake in A549 cells was assessed by flow cytometry. Silencing of target proteins was determined by Luciferase and MTT assays. Sub-G1 analysis was performed to evaluate apoptosis following co-delivery of siPLK1 and Doxorubicin (Dox).RESULTS: Zeta potential and siRNA complexation profile obtained for all hybrids were comparable to those achieved with cationic liposomes. ox-MWNTs-NH3 (+) showed greater extent of interaction with cationic liposomes compared to MWNTs-NH3 (+). ox-MWNTs-NH3 (+) was able to protect siRNA from nuclease-mediated degradation. Enhanced cellular uptake of both the carrier and loaded siRNA in A549 cell, were observed for this hybrid compared to the liposomal carrier. A synergistic pro-apoptotic effect was obtained when siPLK1 silencing was combined with doxorubicin treatment for the hybrid:siRNA complexes compared to the lipoplexes, in A549 cells in vitro.CONCLUSIONS: f-MWNTs-cationic liposome hybrid designed in this study can serve as a potential vehicle for the co-delivery of siRNA and cytotoxic drugs to cancer cells in vitro.",
author = "Sara Pereira and Jin Lee and Noelia Rubio and Hassan, {Hatem A F M} and Suffian, {Izzat Bin Mohamed} and Wang, {Julie T W} and {Klippstein Martin}, Rebecca and Bel{\'e}n Ballesteros and Al-Jamal, {Wafa' T.} and Al-Jamal, {Khuloud T}",
year = "2015",
month = "10",
doi = "10.1007/s11095-015-1707-1",
language = "English",
volume = "32",
pages = "3293--3308",
journal = "Pharmaceutical Research",
issn = "0724-8741",
publisher = "Springer New York",
number = "10",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Cationic Liposome- Multi-Walled Carbon Nanotubes Hybrids for Dual siPLK1 and Doxorubicin Delivery In Vitro

AU - Pereira, Sara

AU - Lee, Jin

AU - Rubio , Noelia

AU - Hassan, Hatem A F M

AU - Suffian, Izzat Bin Mohamed

AU - Wang, Julie T W

AU - Klippstein Martin, Rebecca

AU - Ballesteros, Belén

AU - Al-Jamal, Wafa' T.

AU - Al-Jamal, Khuloud T

PY - 2015/10

Y1 - 2015/10

N2 - PURPOSE: To formulate f-MWNTs-cationic liposome hybrids for the simultaneous delivery of siPLK1 and doxorubicin to cancer cells.METHOD: f-MWNTs-cationic liposome hybrids were prepared by the thin film hydration method where the lipid film was hydrated with 100 μg/ml or 1 mg/ml of ox-MWNTs-NH3 (+) or MWNTs-NH3 (+) in 5% dextrose. siRNA complexation and protection ability was determined by agarose gel electrophoresis. f-MWNTs and liposome interaction was evaluated using Nile Red (NR) fluorescence spectroscopy. Cellular uptake in A549 cells was assessed by flow cytometry. Silencing of target proteins was determined by Luciferase and MTT assays. Sub-G1 analysis was performed to evaluate apoptosis following co-delivery of siPLK1 and Doxorubicin (Dox).RESULTS: Zeta potential and siRNA complexation profile obtained for all hybrids were comparable to those achieved with cationic liposomes. ox-MWNTs-NH3 (+) showed greater extent of interaction with cationic liposomes compared to MWNTs-NH3 (+). ox-MWNTs-NH3 (+) was able to protect siRNA from nuclease-mediated degradation. Enhanced cellular uptake of both the carrier and loaded siRNA in A549 cell, were observed for this hybrid compared to the liposomal carrier. A synergistic pro-apoptotic effect was obtained when siPLK1 silencing was combined with doxorubicin treatment for the hybrid:siRNA complexes compared to the lipoplexes, in A549 cells in vitro.CONCLUSIONS: f-MWNTs-cationic liposome hybrid designed in this study can serve as a potential vehicle for the co-delivery of siRNA and cytotoxic drugs to cancer cells in vitro.

AB - PURPOSE: To formulate f-MWNTs-cationic liposome hybrids for the simultaneous delivery of siPLK1 and doxorubicin to cancer cells.METHOD: f-MWNTs-cationic liposome hybrids were prepared by the thin film hydration method where the lipid film was hydrated with 100 μg/ml or 1 mg/ml of ox-MWNTs-NH3 (+) or MWNTs-NH3 (+) in 5% dextrose. siRNA complexation and protection ability was determined by agarose gel electrophoresis. f-MWNTs and liposome interaction was evaluated using Nile Red (NR) fluorescence spectroscopy. Cellular uptake in A549 cells was assessed by flow cytometry. Silencing of target proteins was determined by Luciferase and MTT assays. Sub-G1 analysis was performed to evaluate apoptosis following co-delivery of siPLK1 and Doxorubicin (Dox).RESULTS: Zeta potential and siRNA complexation profile obtained for all hybrids were comparable to those achieved with cationic liposomes. ox-MWNTs-NH3 (+) showed greater extent of interaction with cationic liposomes compared to MWNTs-NH3 (+). ox-MWNTs-NH3 (+) was able to protect siRNA from nuclease-mediated degradation. Enhanced cellular uptake of both the carrier and loaded siRNA in A549 cell, were observed for this hybrid compared to the liposomal carrier. A synergistic pro-apoptotic effect was obtained when siPLK1 silencing was combined with doxorubicin treatment for the hybrid:siRNA complexes compared to the lipoplexes, in A549 cells in vitro.CONCLUSIONS: f-MWNTs-cationic liposome hybrid designed in this study can serve as a potential vehicle for the co-delivery of siRNA and cytotoxic drugs to cancer cells in vitro.

U2 - 10.1007/s11095-015-1707-1

DO - 10.1007/s11095-015-1707-1

M3 - Article

C2 - 26085038

VL - 32

SP - 3293

EP - 3308

JO - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 10

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454